Khloris Biosciences Competitors and Similar CompaniesClear all

Khloris Biosciences's competitors and similar companies include Clovis Oncology, Takeda, Puma Biotechnology and Ablynx.
Khloris Biosciences
Khloris Biosciences
Khloris Biosciences is a biotechnology company developing the treatment of cardiovascular, oncology, and other diseases.
Clovis Oncology
Clovis Oncology
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents.
Takeda
Takeda
Takeda Pharmaceutical is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
Ablynx
Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
Founding Date
Founding Date
2017
Founding Date
2009
Founding Date
1781
Founding Date
2010
Founding Date
2001
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Mountain View, US HQ
Locations
Boulder, US HQ
Paris, FR
München, DE
Dublin, IE
Milano, IT
Madrid, ES
Zürich, CH
see more
Locations
Tokyo, JP HQ
Buenos Aires, AR
The Rocks, AU
Linz, AT
Wien, AT
Wien, AT
Lessines, BE
see more
Locations
Los Angeles, US HQ
Locations
Gent, BE HQ
Employees
Employees
1214% decrease
Employees
4843% increase
Employees
49,281
Employees
27214% decrease
Employees
156
Valuation ($)
Valuation ($)
N/A
Valuation ($)
10.6 m
Valuation ($)
43.7 b
Valuation ($)
136.8 m
Valuation ($)
N/A

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$148.8m (FY, 2021)
Revenue (est.)
¥4.3t (FY, 2024)
Revenue (est.)
$235.6m (FY, 2023)
Revenue (est.)
€85.2m (FY, 2016)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
¥698.7b (FY, 2024)
Cost of goods
$62.7m (FY, 2023)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
¥3.6t (FY, 2024)
Gross profit
$173m (FY, 2023)
Gross profit
N/A
Net income
Net income
N/A
Net income
($264.5m) (FY, 2021)
Net income
¥144.2b (FY, 2024)
Net income
$21.6m (FY, 2023)
Net income
(€1.1m) (FY, 2016)

Funding

Total funding raised
Total funding raised
$ 5m
Total funding raised
$ 357m
Total funding raised
$ 57.8m
Total funding raised
$ 172m
Total funding raised
$ 498.8m
For sources of this data, please see the company profile

View Company Profiles

Clovis Oncology
HQ
Boulder, US
Employees
484↑ 3% increase

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents.

View company
Takeda
HQ
Tokyo, JP
Employees
49,281

Takeda Pharmaceutical is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.

View company
Puma Biotechnology
HQ
Los Angeles, US
Employees
272↓ 14% decrease

Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.

View company
Ablynx
HQ
Gent, BE

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.

View company